Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

114.77
-1.3700-1.18%
Post-market: 114.51-0.2600-0.23%19:59 EDT
Volume:5.50M
Turnover:634.35M
Market Cap:142.41B
PE:22.90
High:118.13
Open:116.90
Low:114.52
Close:116.14
52wk High:121.83
52wk Low:75.91
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.87
T/O Rate:0.44%
Dividend:3.12
Dividend Rate:2.72%
EPS(TTM):5.01
EPS(LYR):0.3849
ROE:33.40%
ROA:12.62%
PB:7.24
PE(LYR):298.16

Loading ...

Gilead Sciences’ Promising Phase 3 Study in Lung Cancer Treatment

TIPRANKS
·
11 hours ago

Gilead Sciences Advances HIV-1 Treatment with New Clinical Study on GS-3242

TIPRANKS
·
11 hours ago

Gilead Sciences Advances Ulcerative Colitis Treatment with New Filgotinib Study

TIPRANKS
·
11 hours ago

Gilead Sciences Advances in NSCLC Treatment: Key Study Update

TIPRANKS
·
11 hours ago

Suze Orman reveals her favorite stock right now and the investing mistake that shaped her strategy

Dow Jones
·
Yesterday

Gilead Sciences Advances Lung Cancer Treatment with New Clinical Study

TIPRANKS
·
Aug 23

Suze Orman is known for money advice - now she's sharing her stock picks and biggest investing mistake

Dow Jones
·
Aug 22

Gilead Sciences (GILD) Receives a Buy from BMO Capital

TIPRANKS
·
Aug 22

Gilead Sciences Stock (GILD) Turns Negative As CVS Says No To HIV Prevention Drug

TIPRANKS
·
Aug 22

Gilead Sciences Advances Ulcerative Colitis Treatment with Filgotinib Study

TIPRANKS
·
Aug 22

Why Gilead Sciences (GILD) Shares Are Sliding Today

stock_story_highlight
·
Aug 21

Gilead's Kite to Acquire Interius BioTherapeutics for $350 Million to Boost In Vivo CAR Therapeutics

Reuters
·
Aug 21

Kite: Transaction With Interius Is Expected to Reduce Gilead's Gaap and Non-Gaap 2025 EPS by Approximately $0.23-$0.25

THOMSON REUTERS
·
Aug 21

Kite to Acquire Interius Biotherapeutics to Advance in Vivo Platform

THOMSON REUTERS
·
Aug 21

Kite: Proposed Deal for $350 Mln.

THOMSON REUTERS
·
Aug 21

Shares of Gilead Down 2.9% Premarket After Reuters Report CVS Holds off Adding Co's New Hiv Prevention Shot to Drug Coverage Lists

THOMSON REUTERS
·
Aug 21

EXCLUSIVE-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists

Reuters
·
Aug 21

Exclusive - CVS Health Not yet Adding Gilead Sciences' New Hiv Prevention Injection Yeztugo to Its Commercial or Aca Plans

THOMSON REUTERS
·
Aug 21

Gilead Sciences Inc. to Present at Cantor Global Healthcare Conference

Reuters
·
Aug 21

Bernstein Adjusts Price Target on Gilead Sciences to $135 From $120, Maintains Outperform Rating

MT Newswires Live
·
Aug 20